Total parenteral nutrition associated cholestasis: A predisposing factor for sepsis in surgical neonates? by Bos, A.P. (Albert) et al.
Eur J Pediatr (1990) 149 :351-353 
European Journal of 
Pediatrics 
9 Springer-Verlag 1990 
Total parenteral nutrition associated cholestasis: 
a predisposing factor for sepsis in surgical neonates? 
A. P. Bos, D. Tibboel, F.W.J. Hazebroek, J. H. Bergmeijer, E.J. van Kalsbeek, and J. C. Molenaar 
Paediatric Surgical Intensive Care Unit, Department ofPaediatric Surgery, Sophia Children's Hospital, Erasmus University Medical School, 
Gordelweg 160, 3038 GE Rotterdam, The Netherlands 
Abstract. Of 496 neonates and infants less than i year of age 
admitted to the paediatric surgical intensive care unit (PSICU) 
over a 5 year period (1983-1987), 94 required total parenteral 
nutrition (TPN) for more than 14 consecutive days, generally 
due to congenital anomalies of the digestive tract. Cholestasis 
occurred in 15 of them and 12 of these patients developed sep- 
sis. In contrast, of the 79 patients on TPN that remained free 
from cholestasis, only 23 developed sepsis. The mortality rate 
for the TPNAC-group was substantially higher than for the 
group without TPNAC. It is suggested that development of 
TPNAC might lead to impairment of non-specific cellular im- 
munity in neonates. 
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Introduction 
Survival of neonates with congenital anomalies uch as ab- 
dominal wall defects, intestinal atresia, necrotizing enteroco- 
litis and short bowel syndrome has increased in the last de- 
cades. The administration f prolonged total parenteral nutri- 
tion (TPN) has become standard procedure in the manage- 
ment of these patients. Cholestasis i one of many complica- 
tions that have been associated with TPN [6]. The aetiology of 
TPN-associated cholestasis (TPNAC) is unknown, but pre- 
maturity, low birth weight, the administration of amino acids 
and lack of enteral feeding have all been implicated as con- 
tributing factors [12]. Analysing the incidence of sepsis in our 
paediatric surgical intensive care unit (PSICU), we found a 
high frequency in TPNAC patients. This suggests that the de- 
velopment of cholestasis in patients who require prolonged 
TPN might be a predisposing factor for the occurrence of sep- 
sis. In order to evaluate this premise, we carried out a retro- 
spective investigation of sepsis in patients that received pro- 
longed TPN and developed cholestasis. 
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Abbreviations: PSICU = pediatric surgical intensive care unit; 
TPN = total parenteral nutrition; TPNAC = total parenteral nu- 
trition associated cholestasis; 
Patients and methods 
From January 1983 to December 1987, a total of 496 infants 
with congenital anomalies were admitted within 1 month after 
birth to the PSICU of Sophia Children's Hospital, Rotterdam. 
The patients that had received TPN for more than 14 consecu- 
tive days were considered for a retrospective evaluation. Ex- 
cluding patients with congenital anomalies of the liver, such as 
biliary atresia, or hepatitis, and those who developed sepsis 
within the first 14 days of TPN, the study population finally 
consisted of 94 patients. 
The perinatal parameters for these 94 patients were asses- 
sed, such as duration of gestation, birth weight, gender, mor- 
bidity and mortality and diagnosis at admission. Depending 
on the occurrence of cholestasis, these patients were assigned 
to either one of two groups, with the diagnosis of TPNAC de- 
fined by the following criteria: 
1. The administration f TPN for at least 14 consecutive days. 
2. A conjugated bilirubin level of 1.5 mg/dl or higher. 
3. At  least 50% of the total serum bilirubin in the direct react- 
ing fraction. 
4. Other problems associated with direct hyperbilirubin- 
aemia, were ruled out either by analysis of serum or urine 
(e.g. infections, alpha-l-antitrypsin deficiency, galactosaemia) 
or ultrasound (malformation of bile ducts). 
The nutritional regimen for all patients included amino acids 
(Amino-venDs, Fresenius AG, Bad Homburg, FRG), fat (Intra 
lipid, Kabi-Vitrum, Stockholm, Sweden) and dextrose provid- 
ing a daily intake of 100-120kcal/kg, 2-2.5 g/kg of protein 
and 2-3g/kg of fat. Vitamins and trace-elements (Pedel, 
Kabi-Vitrum, Stockholm, Sweden) were also administered. 
The development of sepsis was noted per group. In cases 
of clinical suspicion of sepsis, septic episodes were only taken 
into account if substantiated by positive cultures of blood, 
CSF, urine, or central venous catheters. Data analysis in- 
cluded chi-square analysis of categorical data. The Student's t-
test was used for comparison of mean data. Statistical signifi- 
cance was based on P < 0.05. 
Results 
Of the 94 patients under study, 15 (16%) developed TPNAC, 
while 79 (84%) remained free from cholestasis. In both groups 
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Table 1. Clinical data 
Patients Patients P 
with TPNAC without TPNAC 
Patients 15 79 
Duration 
of gestation (week) 
Mean 36.5 36.5 NS 
Range 31-40 27-42 
Birth weight (g) 
Mean 2600 2450 NS 
Range 2300-3 965 1000-4030 
Gender 
Male 11 42 NS 
Female 4 37 
Sepsis 12 (80%) 23 (29%) 0.006 
Mortality 3 (20%) 1 (1.3%) 0.009 
Table 2. Characteristics ofsepsis 
Patients Patients 
with without 
TPNAC TPNAC 
Number of patients 15 79 
Patients with sepsis 12 (80%) 23 (29%) 
Number of septic episodes 16 25 
Gram-positive organisms 5 10 
S. epidermidis 3 8 
S. aureus 2 2 
Gram-negative organisms 8 8 
Klebs. pneumoniae 5 4 
Pseud. aeruginosa 2 i 
E. coli 1 3 
Other organisms 3 7 
the incidence of abdominal wall defects, intestinal atresia and 
NEC was equally distributed. Table 1 gives the comparative 
clinical data for the two groups. There was a significant differ- 
ence in the frequency of sepsis between the two groups, 
amounting to 80% (12 of 15 patients) for the TPNAC group 
versus 29% (23 of 79 patients) for the other group (P = 0.006). 
In the TPNAC group sepsis occurred 10-15 days (median 13 
days) after cholestasis had developed. The mortality rate for 
the TPNAC group was 20%, significantly higher than the 
1.3% for the other group (P = 0.009). Table 2 gives the char- 
acteristics of sepsis as it occurred in either group. In the 
TPNAC group, 12 patients (80%) developed sepsis, with the 
number of septic episodes amounting to 16. In comparison, 23 
(29%) of the patients without cholestasis developed sepsis, 
amounting to 25 septic episodes. In the TPNAC group, the 
majority of the septic episodes were due to gram-negative or- 
ganisms, while gram-positive organisms predominated in the 
other group. Statistical significance was not achieved in either 
group. The three remaining septic episodes in the TPNAC 
group were due to Candida albicans. In the group without 
TPNAC, seven septic episodes were due to other organisms, 
mainly consisting of urinary tract infection caused by Entero. 
coccus. Sepsis-related mortality in the TPNAC group was 
caused by Pseudomonas aeruginosa and Staphylococcus au- 
reus. The one death in the group without TPNAC was also re- 
lated to sepsis, which was caused by Staphylococcus epider- 
midis. 
Discussion 
Long-term TPN has become a lifesaving treatment for neon- 
ates with surgical anomalies that compromise intestinal func- 
tion. Peden and coworkers first reported the occurrence of 
cholestatic liver disease in a neonate who died following pro- 
longed TPN [6]. Fifteen of our series of 94 patients who re- 
ceived TPN for over 14 consecutive days, developed choles- 
tasis. This represents an incidence of 16%, a figure that com- 
pares favourably with an incidence of approximately 30% re- 
ported in the literature [4, 7]. The pathogenesis of the TPNAC 
syndrome is considered to be multifactorial [12]. Prematurity, 
low birth weight and amino acid components ofTPN, in com- 
bination with a lack of enteral feeding have all been associated 
with the syndrome [2]. In our study, clinical characteristics a - 
sociated with the development of TPNAC, such as low birth 
weight and prematurity, failed to achieve statistical signifi- 
cance. 
Sepsis per se can be an aetiological factor for the develop- 
ment of cholestasis [12]. Therefore we excluded the patients 
from study, who became septic during the first 14 days of TPN. 
After TPNAC had occurred, 80% of the patients developed 
sepsis, compared with 29% without cholestasis. This differ- 
ence was not related to the number of indwelling central ve- 
nous catheters in either group. 
Gram-negative infections predominated in the TPNAC- 
group and were responsible for fatal septic episodes in two pa- 
tients. Yeast septicaemia contributed to a prolonged stay in 
the PSICU for three other patients. 
Little is known of the effect of cholestasis on host immuni- 
ty. Recent review articles in the paediatric literature on neo- 
natal cholestasis [1] and neonatal immunity [13] do not dwell 
on this aspect. However, in 1975 Rola-Pleszczynski et al. de- 
scribed inhibitory effects of bilirubin on cell-mediated immu- 
nity as measured by lmyphoproliferative responses to phyto- 
haemagglutinin i  adult and cord blood lymphocytes [8]. Ex- 
perimental biliary obstruction in rats showed impairment of 
both in vitro and in vivo specific cellmediated immunity. This 
impairment was partly reversible by internal biliary drainage 
[9]. Recently, delayed hypersensitivity was observed in jaun- 
diced, adult patients, confirming depression of cell-mediated 
immunity in these patients [3]. Further investigation of non- 
specific cellular immune function in a rat model of bile duct 
ligation showed impairment of phagocytic ability of poly- 
morphonuclear leukocytes as well as pulmonary alveolar mac- 
rophages. Direct migration and superoxide release were not 
affected [10]. 
We suggest that also in neonates impairment of non-specif- 
ic, cellular immunological mechanisms may occur in associa- 
tion with cholestasis and would account for the increased sus- 
ceptibility to sepsis in TPNAC patients. One of the essential 
processes that must take place prior to phagocytosis, is op- 
sonization of bacteria which is partly dependent on the pres- 
ence of complement and fibronectin. One could only specu- 
late whether fibronectin deficiency plays a role in this patient 
group, although fibronectin deficiency already has been re- 
lated to sepsis in adults [5, 11]. 
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